Increased levels of specific leukocyte- and platelet-derived substances during normal anti-tetanus antibody synthesis in patients with inactive Crohn disease

Scandinavian Journal of Gastroenterology

Volumn 36, Issue 3, 2001, Pages 265-269

  Nielsen, H J ^a   Mortensen, T ^a   Holten Andersen, M ^a   Brunner N ^a   Sorensen S ^a   Rask Madsen, J ^a  

^a HVIDOVRE HOSPITAL   (Denmark)

Author keywords

Anti tetanus antibodies; Crohn disease; CRP; Histamine; IL 6; MPO; PAI 1; Tetanus toxoid; TIMP 1; TNF ; VEGF

Indexed keywords

C REACTIVE PROTEIN; HISTAMINE; INTERLEUKIN 6; MYELOPEROXIDASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TETANUS ANTIBODY; TETANUS TOXOID; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE PRODUCTION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNIZATION; IMMUNOMODULATION; IMMUNOREGULATION; INTESTINE MUCOSA; LEUKOCYTE ACTIVATION; MALE; PRIORITY JOURNAL; THROMBOCYTE FUNCTION;

EID: 0035087024     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/003655201750074537     Document Type: Article

References (31)

1. Microbial factors in the pathogenesis of Crohn's disease, ulcerative colitis, and experimental intestinal inflammation
2. Systemic tumour necrosis factor in Crohn's disease: Relationship to disease activity and circulation acute phase reactants
3. Secretion imbalance between tumour necrosis factor and its inhibitor in inflammatory bowel disease
4. Antibodies in patients with inflammatory bowel disease and the apparent influence of medications
5. Defective generation of tetanus-specific antibody-producing B cells after in vivo immunization of Crohn's disease and ulcerative colitis patients
6. Defective memory B cell formation in patients with inflammatory bowel disease following tetanus toxoid booster immunization
7. Growth factors in inflammatory bowel disease
8. Clinical relevance of serum interleukin-6 in Crohn's disease: Single point measurements, therapy monitoring, and prediction of clinical relapse
9. Mucosal histamine and histamine reaction in Crohn's disease, ulcerative colitis, and allergic enteropathy
10. Increased production of vascular endothelial growth factor by peripheral blood mononuclear cells in patients with inflammatory bowel disease
11. Distinct expression profiles of stromelysin-2 (MMP-10), collagenase-3 (MMP-13), macrophage metalloelastase (MMP-12), and tissue inhibitor of metalloproteinases-3 (TIMP-3) in intestinal ulcerations
12. Coagulation and fibrinolysis in children, adolescents, and young adults with inflammatory bowel disease
13. Myeloperoxidase concentrations in the stool as a new parameter of inflammatory bowel disease
14. Incidence and prevalence of Crohn's disease in the Copenhagen County from 1962-87: A six fold increase in incidence
15. ELISA for the routine determination of antitoxic immunity to tetanus
16. Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer
17. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis
18. Elevated serum vascular endothelial growth factor in children and young adults with Crohn's disease
19. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: Significance for VEGF measurements and cancer biology
20. Soluble vascular endothelial growth factor in various blood transfusion components
21. Granules of the human neutrophilic polymorphonuclear leukocyte
22. Time-dependent histamine release from stored human blood products
23. Bacteria-induced release of bioactive substances from white cells and platelets
24. Anti-idiotypic antibodies and circulating immune complexes after immunisation with tetanus toxoid
25. Role of repetitive antigen patterns for induction of antibodies against antibodies
26. Anti-interleukin-6 antibodies in normal human serum
27. Autoantibodies to myeloperoxidase in brown Norway rats treated with mercuric chloride
28. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis
29. Absence of host plasminogen activator inhibitor-1 prevents cancer invasion and vascularization
30. Association of plasma concentrations of plasminogen activator inhibitor type-1 and survival in patients with colorectal cancer
31. Intestinal cancer risk and mortality in patients with Crohn's disease